Konstantin Föhse, Büsra Geckin, Martijn Zoodsma, Gizem Kilic, Zhaoli Liu, Rutger J Röring, Gijs J Overheul, Josephine van de Maat, Ozlem Bulut, Jacobien Hoogerwerf, Jaap Ten Oever, Elles Simonetti, Heiner Schaal, Ortwin Adams, Lisa Müller, Philipp Niklas Ostermann, Frank L van de Veerdonk, Leo A B Joosten, Bart L Haagmans, Reinout van Crevel, Ronald P van Rij, Corine GeurtsvanKessel, Marien I de Jonge, Yang Li, Jorge Domínguez-Andrés, Mihai G Netea
The mRNA-based BNT162b2 protects against severe disease and mortality caused by SARS-CoV-2 via induction of specific antibody and T-cell responses. Much less is known about its broad effects on immune responses against other pathogens. Here, we investigated the adaptive immune responses induced by BNT162b2 vaccination against various SARS-CoV-2 variants and its effects on the responsiveness of immune cells upon stimulation with heterologous stimuli. BNT162b2 vaccination induced effective humoral and cellular immunity against SARS-CoV-2 that started to wane after six months...
September 4, 2023: Clinical Immunology: the Official Journal of the Clinical Immunology Society